A new Nature Medicine study analyzes how epigenetic clocks respond to longevity interventions. Learn why biological age tests do not guarantee skin aging results.
In August 2026, a new study published in Nature Medicine revealed how different epigenetic aging clocks respond to human longevity interventions. Yale-led researchers examined a harmonized database called TranslAGE to see if these biomarkers shift consistently. The work involved collaborators from Harvard University, the University of California San Diego, and epigenetic-testing company TruDiagnostic. The paper underscores that not all biological markers move in the same way when tested against lifestyle or medical changes. The Nature Medicine paper is part of a broader effort to identify biomarkers that could shorten longevity studies. These studies would otherwise require decades of follow-up. The paper's authors did not claim that these biomarkers have already been validated as surrogate endpoints for lifespan or healthspan.
Epigenetic clocks estimate biological characteristics from DNA-methylation patterns rather than simply measuring chronological age. Steve Horvath introduced the first widely recognized epigenetic clock in 2013, and subsequent generations increasingly attempted to capture biological health and mortality-related risk. The Nature Medicine analysis examined 16 epigenetic clocks and 94 additional DNA-methylation biomarkers across 51 longitudinal intervention studies. The interventions discussed included dietary approaches, lifestyle changes, smoking cessation and pharmacological treatments.
In this analysis, clocks trained to predict mortality or pace of aging showed the strongest responses. Older clocks trained primarily to predict chronological age were less consistently responsive than newer tools. The most responsive newer-generation biomarkers highlighted in the coverage were DunedinPACE, PCGrimAge, GrimAgeV2, PCPhenoAge and SystemsAge. DunedinPACE appeared broadly responsive across lifestyle studies, while GrimAgeV2 and PCGrimAge were particularly sensitive to drug interventions.
The researchers described explainable clocks with multiple subscores as offering greater specificity and mechanistic insight than single-score clocks. The article connected potentially explainable biomarker signals with biological systems including inflammation, metabolism, kidney function, lung function and musculoskeletal function. The study's stated purpose was to help future trials select appropriate biomarkers and interventions. The authors also aimed to refine study durations, sample sizes and multiple-testing strategies.
The data reveals that real-world outcomes vary significantly based on the specific intervention. A summary of the study reported that 19 interventions significantly reduced epigenetic age across the 16-clock panel. However, only 13 remained significant after correction for multiple comparisons. Five interventions actually increased epigenetic age, and 26 showed no significant overall effect.
The study reported stronger average DNA-methylation responses for pharmacological interventions compared to lifestyle interventions. The average effect size was -0.09307 for pharmacological treatments and -0.0393 for lifestyle interventions. Interventions like Mediterranean-style dietary patterns and anti-TNF therapies emerged as relatively reproducible examples. Meanwhile, findings related to supplements and medical procedures were less consistent.
Across the 51 interventions, several biomarkers showed larger decreases in disease populations. This occurred potentially because those participants had greater baseline biological disruption and more room for improvement. This remains an interpretation rather than proof of clinical benefit. The DO-Health and COSMOS analyses reported statistically significant but modest effects on newer-generation clocks. However, those analyses were not included in the TranslAGE dataset because of data-availability constraints.
A favorable change in one epigenetic clock should not be treated as proof that aging, healthspan, or lifespan has improved. The paper found that population characteristics and study duration heavily influenced biomarker responsiveness. David Furman of the Buck Institute for Research on Aging stated that consistent clock movement is necessary rather than sufficient for a surrogate endpoint. He emphasized that it remains unresolved whether short-term changes in an epigenetic clock correspond to later gains in healthspan.
This scientific uncertainty directly shapes how our team at Younell evaluates longevity claims. "I remember speaking with a dermatologist who told me her patients were coming in with severe anxiety about normal skin aging. That anxiety was driven entirely by social media filters and aggressive marketing. That conversation became a cornerstone of our philosophy. We decided right then that our publication would never frame natural changes like wrinkles or thinning hair as personal failures." Today, proprietary biological age scores can easily trigger that same anxiety if consumers assume a single blood test dictates their overall health.
Stronger evidence would require larger randomized trials with repeated biomarker measurements and clinical outcomes. These outcomes include disease risk, physical function, cognition, preserved independence and survival. Furthermore, supplement findings should be interpreted cautiously because the available trials were often small, short and heterogeneous. Furman said individual nutraceuticals rarely move composite biological-age markers reliably at the population level.
The study involved researchers connected with commercial and patented biomarker technologies. SystemsAge was patented by two authors. Some authors consulted for TruDiagnostic and FOXO Biosciences, while several authors were TruDiagnostic employees who developed OMICmAge. A separate research direction involves the ARPA-H PROSPR/THRIVE program, which combines wearable, clinical and multi-omic data across approximately 20 aging cohorts. This program studies whether intrinsic-capacity trajectories connect more directly with meaningful health outcomes.
For women evaluating their nutrition and longevity routines, this research offers clear guidance on biological testing. Consumers should identify what a clock was trained to measure before buying or repeating a test. Clocks predict specific outcomes like chronological age, mortality risk, or a specific physiological system. It is wise to prefer tests that disclose the biomarker methodology and its validation context.
Do not interpret a favorable result as proof that a supplement is improving skin biology. Skin, hair, and collagen claims require their own outcomes, such as validated clinical appearance scores or elasticity measures. The paper provides evidence about blood-based aging biomarkers, not direct proof of improved skin, hair or collagen. You can better grasp cellular function by reading about the core biology behind cellular aging. We also suggest reviewing our guide on how genetics and epigenetics influence aging.
Consumers should ask whether a test reports uncertainty, repeatability and the specific outcome it predicts. A clock that is responsive in a clinical trial may not yet be validated for individual consumer decision-making. Because blood-based epigenetic change is not automatically a skin-aging result, beauty outcomes must be measured separately. For instance, consumers can evaluate their own progress using a reliable self-assessment framework. Connecting these targeted assessments with general physical habits offers a more grounded approach to wellness.
We recommend prioritizing interventions with broader health evidence, like sustained dietary quality and exercise. Furman's expert interpretation placed targeted anti-inflammatory pharmacology first. He ranked sustained Mediterranean-style dietary change second, exercise and lifestyle programs third, and supplements fourth. Tracking biological markers requires patience and a focus on repeatable data over time. The study supports testing biomarkers as candidate tools for researchers, not as definitive answers for individual consumer decision-making.
This research highlights the growing need to link molecular aging measurements with clinically meaningful functional assessments. Furman's team developed the IC Clock to assess practical, everyday functional capacity. The tool relies on measurements of cognition, locomotion, psychological well-being, sensory ability and vitality across 1,014 people. As epigenetic clocks become more accessible, will the beauty and wellness industries adopt transparent, explainable biomarkers, or will they continue to rely on proprietary scores? The next step is to see if larger, repeated-measurement trials can finally connect these molecular shifts to tangible improvements in our daily lives.
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
